Antiproliferative effect of somatostatin analogs – PROMID study Commentary
Article Sidebar
Published:
May 31, 2011
Main Article Content
Abstract
None
Downloads
Download data is not yet available.
Article Details
How to Cite
1.
Kos-Kudła B, Rosiek V. Antiproliferative effect of somatostatin analogs – PROMID study. OncoReview [Internet]. 2011May31 [cited 2024Nov.23];1(2(2):116-21. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/243
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Rinke A., Müller H.H., Schade-Brittinger C. et al.: Placebo-controlled, doubleblind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group. J. Clin. Oncol. 2009; 27: 4656-4663.
2. Chua Y.J., Michael M., Zalcberg J.R. et al.: Antitumor effect of somatostatin analogs in neuroendocrine tumors. J. Clin. Oncol. 2010; 28(3): e41-e42.
3. Arnold R., Müller H.H., Rinke A.: Reply to Y.J. Chua et al. J. Clin. Oncol. 2010; 28(3): e43-e44.
4. Arnold R., Rinke A., Klose K.J. et al.: Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial. Clin. Gastroenterol. Hepatol. 2005; 3: 761-771.
5. Oberg K.: Key Peer-Reviewed Papers from Leading Jounals. NET Journal Club 2010; 1(2): 5-23.
6. Guzy neuroendokrynne układu pokarmowego. Kos-Kudła B. (red.). Via Medica, Gdańsk 2010: 1-362.
2. Chua Y.J., Michael M., Zalcberg J.R. et al.: Antitumor effect of somatostatin analogs in neuroendocrine tumors. J. Clin. Oncol. 2010; 28(3): e41-e42.
3. Arnold R., Müller H.H., Rinke A.: Reply to Y.J. Chua et al. J. Clin. Oncol. 2010; 28(3): e43-e44.
4. Arnold R., Rinke A., Klose K.J. et al.: Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial. Clin. Gastroenterol. Hepatol. 2005; 3: 761-771.
5. Oberg K.: Key Peer-Reviewed Papers from Leading Jounals. NET Journal Club 2010; 1(2): 5-23.
6. Guzy neuroendokrynne układu pokarmowego. Kos-Kudła B. (red.). Via Medica, Gdańsk 2010: 1-362.